Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL866190 | 1.00 | ALDH1A1 (0.38) | ALDH1A1LMNAGPR119KMT2AMAPK1 | |
| SCHEMBL864900 | 0.90 | GPR119 (0.38) | GPR119KMT2AMAPK1DPP4 | |
| SCHEMBL864901 | 0.90 | GPR119 (0.38) | GPR119KMT2AMAPK1DPP4 | |
| SCHEMBL864617 | 0.89 | DPP4 (0.40) | ALDH1A1LMNAGPR119KMT2AMAPK1 | |
| SCHEMBL864618 | 0.89 | DPP4 (0.40) | ALDH1A1LMNAGPR119KMT2AMAPK1 | |
| SCHEMBL864616 | 0.89 | DPP4 (0.40) | ALDH1A1LMNAGPR119KMT2AMAPK1 | |
| SCHEMBL864544 | 0.85 | CHRM2 (0.40) | GPR119DPP4CHRM2 | |
| SCHEMBL864545 | 0.85 | CHRM2 (0.40) | GPR119DPP4CHRM2 | |
| SCHEMBL864347 | 0.84 | DPP4 (0.38) | GPR119DPP4 | |
| SCHEMBL10104810 | 0.84 | DPP4 (0.38) | GPR119DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | ALDH1A1 1300/4885LMNA 4011/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.